Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278

Similar articles for PubMed (Select 22072815)

1.

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Hideshima T, Richardson PG, Anderson KC.

Mol Cancer Ther. 2011 Nov;10(11):2034-42. doi: 10.1158/1535-7163.MCT-11-0433. Review.

2.

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.

Jagannath S, Dimopoulos MA, Lonial S.

Leuk Res. 2010 Sep;34(9):1111-8. doi: 10.1016/j.leukres.2010.04.001. Epub 2010 May 15. Review.

PMID:
20472288
3.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
4.

Proteasome inhibitor therapy in multiple myeloma.

Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC.

Mol Cancer Ther. 2005 Apr;4(4):686-92. Review.

5.

Proteasome inhibition for treatment of multiple myeloma: clinical update.

Stadtmauer EA.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S10-5. Review.

PMID:
19795531
6.

Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.

Exp Cell Res. 2009 Aug 15;315(14):2471-8. doi: 10.1016/j.yexcr.2009.04.019. Epub 2009 May 3.

PMID:
19410573
7.

Current status of bortezomib in the treatment of multiple myeloma.

Cavo M.

Curr Hematol Malig Rep. 2007 May;2(2):128-37. doi: 10.1007/s11899-007-0018-y. Review.

PMID:
20425361
8.

[Proteasome inhibitors].

Saeki Y, Fukunaga K, Tanaka K.

Nihon Rinsho. 2010 Oct;68(10):1818-22. Review. Japanese.

PMID:
20954323
9.

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.

Ludwig H, Khayat D, Giaccone G, Facon T.

Cancer. 2005 Nov 1;104(9):1794-807. Review.

10.

Proteasome inhibition in multiple myeloma.

Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.

Eur J Cancer. 2006 Jul;42(11):1623-39. Epub 2006 Jul 3. Review.

PMID:
16820291
11.
12.

The proteasome: a novel target for anticancer therapy.

Montagut C, Rovira A, Albanell J.

Clin Transl Oncol. 2006 May;8(5):313-7. Review.

PMID:
16760005
13.

Bortezomib for multiple myeloma.

Popat R, Joel S, Oakervee H, Cavenagh J.

Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. Review.

PMID:
16805719
14.

Bortezomib: a novel therapy approved for multiple myeloma.

Richardson PG, Anderson KC.

Clin Adv Hematol Oncol. 2003 Oct;1(10):596-600. Review.

PMID:
16258456
15.

Proteasome inhibition: a new approach for the treatment of malignancies.

Spano JP, Bay JO, Blay JY, Rixe O.

Bull Cancer. 2005 Nov;92(11):E61-6, 945-52. Review. English, French.

PMID:
16316823
16.

Proteasome inhibition and multiple myeloma.

Kanagasabaphy P, Morgan GJ, Davies FE.

Curr Opin Investig Drugs. 2007 Jun;8(6):447-51. Review.

PMID:
17621873
17.

Proteasome inhibitors in the treatment of B-cell malignancies.

Schenkein D.

Clin Lymphoma. 2002 Jun;3(1):49-55. Review.

PMID:
12141956
18.

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ.

Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. Review.

PMID:
15056047
19.

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Richardson PG, Hideshima T, Anderson KC.

Cancer Control. 2003 Sep-Oct;10(5):361-9. Review.

20.

Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

Tobinai K.

Int J Clin Oncol. 2007 Oct;12(5):318-26. Epub 2007 Oct 22. Review.

PMID:
17929113
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk